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Introduction
The efﬁcacy of the triptans (5-HT1B/1D-receptor
agonists) in treating acute migraine attacks has been
established from the results of approximately 100
double-blind, randomised, parallel-group trials (1–3).
The current challenge facing physicians is how to
optimise the beneﬁts of proven migraine treatments
for individual patients.
Placebo-controlled efﬁcacy trials conducted in aca-
demic and specialty centres do not always translate
into primary care. Furthermore, typical migraine efﬁ-
cacy trials do not address a wide range of common
issues such as treatment non-compliance, changing
physician, drug switching and the tendency for
many patients to discontinue medical management
completely (4–7). For these reasons, there has been
an increasing interest to move beyond traditional
efﬁcacy outcomes to focus on patient-centred mea-
sures, such as quality of life (QOL) and functioning.
A patient-centred approach to measuring efﬁcacy
in migraine treatment studies involves asking each
patient to rate the relative importance of key
outcomes, such as speed of pain relief, duration of
relief (i.e. absence of headache recurrence), improve-
ment in migraine-associated symptoms (e.g. nausea,
photophobia and phonophobia), and risk of side
effects. This method for rating the importance to the
patient of each clinical outcome has been proposed
(8–10), but to our knowledge, has not been used
prospectively in a migraine trial.
The aim of this open-label study was to investigate
the utility of patient-weighted outcomes for
evaluating the effectiveness of eletriptan in the
acute treatment of migraine, in a primary care
setting.
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SUMMARY
Objective: The efﬁcacy of triptans for acute migraine has been well established in
clinical trials but not in primary care, where they are most commonly prescribed.
The aim of this open-label study was to evaluate the effectiveness of eletriptan
40 mg in primary care, using a patient-weighted satisfaction scale. Methods: Eli-
gible patients met International Headache Society criteria for migraine, with 1–6
attacks per month. Patients completed questionnaires at screening and following a
single eletriptan-treated attack. Treatment satisfaction was evaluated using a six-
item Medication Satisfaction Questionnaire (MSQ). MSQ item scores were
weighted, based on the important score ratings, to yield individualised satisfaction
scores. The primary end-point was the difference in weighted satisfaction scores
between the patient’s previous treatment and eletriptan 40 mg. Secondary end-
points assessed quality of life (QOL), functioning and efﬁcacy of treatment.
Results: Of 590 patients screened, 437 completed the study. Degree (95.2%),
time (88.8%) and duration (83.8%) of headache pain relief were rated as most
important by patients. The mean (±SD) total satisfaction score on the MSQ was
higher for eletriptan than previous therapy (2.2 ± 3.0 vs. 0.6 ± 2.4; p < 0.001).
The high level of satisfaction with eletriptan vs. previous treatment reﬂects the
improvements in QOL and functioning observed, and the high headache and pain-
free response rates. Conclusions: Patient-weighted satisfaction with eletriptan
40 mg was higher than with previous treatment for all items. The use of patient-
weighted importance ratings of satisfaction is a promising approach for establish-
ing effectiveness of treatment in primary care.
What’s known
The efﬁcacy of triptans (5-HT1B/1D-receptor agonists)
has been well established in clinical trials, but not
in a primary care setting, where they are most
commonly prescribed. Previous studies have
highlighted the treatment outcomes that are most
important to migraine sufferers (e.g. degree of pain
relief, speed of relief and duration of relief). Asking
patients to rate their treatment in terms of the
treatment outcomes that are most important to
them has been suggested as a useful way of
assessing the effectiveness of a treatment in
primary care.
What’s new
To our knowledge, this is the ﬁrst trial to
prospectively assess patient-rated satisfaction with
treatment as an a priori primary outcome. In
addition to assessing the utility of such a
methodology, this article also discusses the
effectiveness of eletriptan for treating acute
migraine in the primary care setting.
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Patients
Men and women aged 18–65 years were eligible for
inclusion in the study if they met International Head-
ache Society criteria for migraine with or without
aura (11), with an attack frequency of 1–6 migraines
per month, an onset of migraine prior to age 50, and
a minimum illness duration of 1 year. Women were
required to be postmenopausal, surgically sterile or
using a medically accepted form of contraception.
Key exclusion criteria were: (i) the presence of
migraine with prolonged aura, familial hemiplegic
migraine or migrainous infarction; (ii) any acute or
unstable medical condition, clinically signiﬁcant lab-
oratory test or electrocardiography (ECG) abnormal-
ity, or presence of any illness or treatment known to
be a contraindication to the safe use of eletriptan as
summarised in the US prescribing information label;
(iii) the misuse or abuse of alcohol or other sub-
stances, based on the Diagnostic and Statistical Man-
ual of Mental Disorders Version IV (DSM-IV)
criteria; and misuse of analgesics (deﬁned as use of
> 50 g of aspirin or > 100 tablets of analgesics) or
ergotamine (deﬁned as use on > 2 days per week).
Study design
This open-label, single-attack, outpatient study was
conducted at 185 primary care practices in the USA
between August 2003 and May 2004.
At the screening visit, patients with a history of
disabling headaches completed the three-item ID
Migraine
TM (Pﬁzer, Inc, New York, NY, USA) ques-
tionnaire, a validated self-administered instrument
that assesses the presence of nausea, photophobia
and headache-related disability (12). Those who
scored positively on at least two of the three items
were familiarised with the study and asked to pro-
vide written informed consent.
To assess their perceptions of previous treatments
used, patients were asked to complete three baseline
questionnaires at the screening visit: (i) Migraine
Relief Questionnaire (MRQ), (ii) Medication
Satisfaction Questionnaire (MSQ) and (iii) Migraine
Quality of Life Questionnaire (MQOLQ). The MRQ
and MSQ are shown in Table 1. The MRQ assessed
Table 1 The Migraine Relief Questionnaire and the Medication Satisfaction Questionnaire
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the patient. The MSQ assessed patient satisfaction
with their usual migraine therapy on these six
outcomes, and the results of the MRQ were used to
weigh the outcomes per patient. The MSQ is based
on previous research that identiﬁed efﬁcacy-related
determinants of patient satisfaction (5,13). The
MQOLQ is a validated instrument that asks patients
to retrospectively answer 15 questions relating to
QOL associated with the 24-h period following
treatment of their last migraine (14,15).
A medical evaluation consisting of a physical
examination, measurement of vital signs, a 12-lead
ECG and urine pregnancy testing (as appropriate)
was also conducted at screening.
Enrolled patients were provided with two tablets
of eletriptan 40 mg and a headache diary. Patients
were instructed to treat a single migraine attack in
the following 12 weeks with eletriptan 40 mg, taking
it as soon as they were certain they were experiencing
a migraine, after the aura phase (if present) had
ended and the headache phase had begun (within
2 h of onset, if possible). If migraine symptoms
recurred within 24 h postdose, a second dose of ele-
triptan 40 mg was allowed, provided at least 2 h had
elapsed after taking the ﬁrst dose. Rescue medication
was also permitted if subjective headache relief was
inadequate.
Patients recorded the date and time of onset of
their eletriptan-treated migraine immediately
postattack, and completed two questionnaires: (i) the
MQOLQ, to assess QOL associated with eletriptan
use 24 h after ﬁrst dose and (ii) the Functional
Assessment in Migraine, Activities and Participation
Scale (FAIM-A&P), a validated scale derived from the
World Health Organization’s International Classiﬁca-
tion of Impairments, Disability and Handicaps
(ICIDU-2) (16), which assesses the degree to which,
on a seven-point scale (where seven ¼ impaired none
of the time and one ¼ impaired all of the time),
migraine-associated impairment affects patient func-
tioning whilst carrying out common activities. The
FAIM-A&P was completed at baseline, 2 and 4 h
postdose. Patients also recorded headache pain sever-
ity, as rated on a four-point scale (where 3 ¼ severe
and 0 ¼ no pain), at baseline, 2 and 24 h postdose,
and noted whether a second dose of eletriptan or any
rescue medication was taken.
Patients were instructed to return to the study
centre within 2 weeks of their eletriptan-treated
attack to complete two further questionnaires: (i) the
MSQ, to assess treatment satisfaction with eletriptan
40 mg and (ii) a migraine treatment preference ques-
tionnaire, which asked patients about their overall
migraine medication preferences.
At study conclusion investigators rated, on a
seven-point scale (where one ¼ very dissatisﬁed and
seven ¼ very satisﬁed), their satisfaction with ID
Migraine
TM as a tool to: (i) identify migraine sufferers,
(ii) help patients to clearly and effectively communi-
cate their symptoms and (iii) improve patient–physi-
cian dialogue related to headache diagnosis.
Study assessments
The primary end-point was the difference in satisfac-
tion between a patient’s previous migraine treatment
and eletriptan 40 mg, as measured on the six
weighted items of the MSQ. The secondary efﬁcacy
end-points were: (i) the MQOLQ; (ii) the FAIM-
A&P; (iii) 2-h headache response, deﬁned as
improvement in headache intensity to mild or no
pain from a pretreatment level of moderate or severe,
rated on a four-point global intensity scale (no pain,
mild, moderate and severe); (iv) 2-h pain-free
response, deﬁned as improvement to no pain at 2 h
postdose following a pretreatment pain level of mod-
erate or severe, on the four-point scale; (v) sustained
headache response at 48 h postdose, deﬁned as
response within 2 h of the ﬁrst dose of study medi-
cation, no headache recurrence, no use of rescue
medication and no second dose of eletriptan within
the remainder of a 48-h period; (vi) sustained pain-
free response at 48 h deﬁned as pain-free response
within 2 h of the ﬁrst dose of study medication, no
headache recurrence, no rescue medication use and
no second dose of eletriptan within the remainder of
a 48-h period; (vii) patient drug preference, as indi-
cated by the migraine treatment preference question-
naire; and (viii) investigator satisfaction with the ID
Migraine
TM screener. Tolerability was also assessed.
Statistical analyses
As this was an open-label, single-attack study,
descriptive statistics were calculated, but no signiﬁ-
cance testing was performed.
The averaged MSQ scores were weighted based on
the importance values assigned to speciﬁc treatment
attributes at the screening visit using the three-point
MRQ. The MSQ item scores were multiplied by one
if the patient rated the outcome item as ‘not so
important’, two if the patient rated the item as
‘important’ or three if the patient rated the item as
‘very important’. To aid in the interpretation of the
satisfaction score, the MSQ scores were re-coded
from a one to ﬁve rating to a )6 to +6 rating, where
the lowest number corresponded to a rating of ‘very
poor’ and the highest number corresponded to a rat-
ing of ‘excellent’. Descriptive statistics (mean and
standard deviation [SD]) for the weighted scores and
the weighted difference scores were calculated.
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MQOLQ individual and the total domain scores, and
a paired t-test was used to assess the change from
baseline to 24 h postdose.
A standard score was calculated for each patient
from the FAIM-A&P scale as follows: (i) the rating
scale was reversed (one ¼ impaired none of the time;
seven ¼ impaired all of the time) and (ii) the score
on each item was summed to obtain a raw total
score. The raw total score was subsequently trans-
formed to a standardised score of 0–100, with a
higher value indicating improved functioning. A
paired t-test was performed to test the change from
baseline to 2 and 4 h postdose.
The study was conducted according to the Decla-
ration of Helsinki (1996 revision) and is consistent
with the International Conference on Harmoniza-
tion Good Clinical Practice guidelines (17). The
protocol was approved by Ethic Committees at each
site.
Results
Five hundred and ninety patients were screened, of
whom 582 met eligibility criteria and were entered
into the study. The safety sample consisted of 481
patients who took study medication, while the
intent-to-treat sample consisted of all patients who
took study medication and completed the MSQ post-
dose (n ¼ 437).
The baseline characteristics of the safety sample
are summarised in Table 2. The preponderance of
women (85%), and individuals in the 30- to 50-year-
old age range, is typical of most migraine clinical
trials. Patients in the study reported an extensive
array of previous migraine therapies, and many used
a combination of therapies. Most patients utilised
non-migraine speciﬁc acute therapies such as non-
steroidal anti-inﬂammatory drugs (NSAIDs) (31%)
and non-NSAID analgesics (61%). Migraine speciﬁc
drugs (triptans and ergotamine-containing prepara-
tions) were used by 47% of study patients.
The MRQ, completed at the screening visit, pro-
vided data on the relative importance of key clinical
outcomes to the patients. The degree of pain relief was
viewed as very important by the highest proportion of
patients (95.2%), followed by time of pain relief
(88.8%) and duration of pain relief (83.8%) (Table 3).
Results for each patient were used to provide individ-
ual weighting to the MRQ satisfaction items.
Patient satisfaction on the MSQ
Treatment with eletriptan 40 mg vs. usual previous
treatment was associated with higher weighted satis-
faction scores overall and on the six individual items
of the primary outcome measure, the MSQ (Table 4).
For the total sample, the proportion of patients
reporting treatment satisfaction as ‘good-to-excellent’
Table 2 Demographic and clinical characteristics of the
patient population (n ¼ 481)
Patient characteristics
Female, % 85
Age, years
Mean ± SD 39.1 ± 10.6
Range 17—65
Race, %
White 79
Black 11
Others 10
Aura subtype, %
Without aura 47
With aura 29
Mixed 24
Attack frequency in past
3 months, mean ± SD
8.1 ± 4.8
Previous acute migraine therapy*
NSAIDs, % 31
Non-NSAID analgesics, % 61
Migraine-speciﬁc treatment
(triptans, ergot-containing drugs), %
47
*Patients may have used more than one class of therapy.
NSAID, non-steroid anti-inﬂammatory drug.
Table 3 Relative importance of clinical outcomes: results from Migraine Relief Questionnaire at screening (n ¼ 437)
Items
Relative importance
Very important Important Not so important
Degree of headache pain relief, n (%) 416 (95.2) 18 (4.1) 3 (0.7)
Time of pain relief, n (%) 388 (88.8) 47 (10.8) 2 (0.5)
Duration of relief, n (%) 366 (83.8) 68 (15.6) 3 (0.7)
Time to return to usual activities, n (%) 349 (79.9) 85 (19.5) 3 (0.7)
Relief of migraine-associated symptoms, n (%) 317 (72.5) 111 (25.4) 9 (2.1)
Efﬁcacy of migraine treatment outweighs side effects, n (%) 263 (60.2) 153 (35.0) 21 (4.8)
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usual previous treatment on the ﬁrst ﬁve MSQ treat-
ment satisfaction items (p < 0.001; Figure 1). The
proportion of patients reporting ‘agree-to-strongly
agree’ that the beneﬁts of treatment outweighed the
side effects was also higher on eletriptan than previ-
ous treatment, although this was not signiﬁcant
(79% vs. 72%).
Approximately 50% of patients reported ‘fair-to-
very-poor’ satisfaction with previous migraine ther-
apy across each of the MSQ items. Treatment with
eletriptan resulted in a high level of ‘good-to-excel-
lent’ satisfaction on each of the MSQ items in this
subgroup (62–70%; Figure 2). Similarly, in the sub-
group of patients (28%) who reported that the efﬁ-
cacy beneﬁts of their previous migraine therapy did
not outweigh the side effects, 74% of them changed
their rating to ‘agree-to-strongly agree’ after switch-
ing to eletriptan treatment (Figure 3).
Effect of eletriptan on quality of life and
functioning
Treatment with eletriptan was associated with greater
improvement in all aspects of QOL, compared with
previous migraine therapies, as measured using the
MQOLQ (Table 5).
At the time of taking eletriptan, the mean (±SD)
FAIM-A&P score was 23.2 ± 23.3, a score consistent
with clinically signiﬁcant migraine-related impair-
ment in functioning. At 2 h postdose, the mean
FAIM-A&P score had increased by 31.5 points to
54.7 ± 34.5, thus functional impairment was signiﬁ-
cantly reduced (p £ 0.001). At 4 h, the score showed
a further increase to 67.7 ± 36.4.
Efﬁcacy evaluation
For the total sample (n ¼ 437), 62% [95% conﬁ-
dence interval (CI): 51–60%] of patients experienced
2-h headache response and 36% (95% CI: 31–40.3%)
experienced 2-h pain-free response. Headache
response was sustained over 48 h in 33% (95% CI:
25–46%) of patients, and a pain-free response was
sustained in 23% (95% CI: 14–31%).
Patient preference
Of 426 patients who provided preference data, 254
(59.6%) preferred eletriptan 40 mg to all previous
acute migraine treatments they had used.
Table 4 Mean weighted Medication Satisfaction Questionnaire satisfaction scores for six items: eletriptan 40 mg vs.
immediate previous migraine treatment
Items
Immediate previous
treatment score
Eletriptan
40 mg score
Difference
in score p-value
Overall satisfaction scores 0.6 ± 2.4 2.2 ± 3.0 1.6 ± 3.9 < 0.001
Degree of headache pain relief, n (%) 1.2 ± 3.1 2.6 ± 3.5 1.4 ± 4.7 < 0.001
Time of pain relief, n (%) 0.2 ± 3.0 1.8 ± 3.5 1.6 ± 4.6 < 0.001
Duration of pain relief, n (%) )0.1 ± 3.2 2.2 ± 3.9 2.3 ± 4.9 < 0.001
Time to return to usual activities, n (%) )0.1 ± 2.8 1.8 ± 3.1 1.9 ± 4.4 < 0.001
Relief of migraine-associated symptoms, n (%) 0.0 ± 3.0 2.2 ± 3.3 2.2 ± 4.5 < 0.001
Efﬁcacy of migraine treatment outweighs side effects, n (%) 2.5 ± 2.7 2.8 ± 3.1 0.3 ± 3.6 0.0866
Figure 1 Proportion of patients reporting satisfaction as ‘good-to-excellent’: comparison of eletriptan 40 mg with previous
migraine treatment (total sample, n ¼ 437)
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TM
One hundred and forty-three investigators rated their
satisfaction with the ID Migraine
TM screener at study
conclusion. Satisfaction was extremely high on all
items assessed. One hundred and twenty-nine inves-
tigators (90%) were ‘satisﬁed’ or ‘very satisﬁed’ with
the assistance provided by ID Migraine
TM in identi-
fying migraine sufferers, 126 (88%) were ‘satisﬁed’ or
‘very satisﬁed’ with how ID Migraine
TM helped their
patients to clearly and effectively communicate their
symptoms, and 129 (90%) were ‘satisﬁed’ or ‘very
satisﬁed’ that ID Migraine
TM improved patient–phy-
sician dialogue related to headache diagnosis.
Tolerability and safety
Only one adverse event, nausea (2.1%), occurred with
an incidence ‡ 2%. Overall, 10.8% of patients on ele-
triptan reported having at least one adverse event. Five
patients (1.0%) rated their adverse events as ‘severe’.
There was one serious adverse event, which was not
treatment related (a patient was involved in a motor
vehicle accident 3 days after taking eletriptan). No
patients discontinued treatment because of an adverse
event. There were no clinically signiﬁcant changes in
laboratory tests, vital signs or ECG during the study.
Discussion
We report here the results of an open-label, single-
attack study that used patient-centred ratings of
treatment satisfaction as the primary outcome. To our
knowledge, no previous trial has utilised weighted
satisfaction to assess the primary, a priori end-point.
The MRQ indicates that the three most important
treatment outcomes for patients were degree of pain
relief (95%), time of pain relief (89%) and duration
of relief (84%). These results reﬂect those reported
by Lipton and Stewart (5) with complete pain relief
(87%), no recurrence (86%) and rapid onset of relief
(83%) rated most highly by migraine sufferers. A
Figure 3 Do the efﬁcacy beneﬁts of therapy outweigh the
side effects? Results for total sample and the poor
tolerability subgroup that switched to eletriptan 40 mg
from previous migraine treatment
Table 5 Mean (±SD) improvement in Migraine Quality
of Life Questionnaire (MQOLQ) domain scores:
comparison of the effect of previous and current
treatment on quality of life (n ¼ 416)
MQOLQ domain Previous treatment Eletriptan 40 mg
Symptoms* +10.3 ± 4.5 +15.2 ± 4.9
Feelings/concerns +8.7 ± 4.5 +13.8 ± 5.6
Work* +10.2 ± 4.8 +14.4 ± 5.7
Social/interpersonal +9.7 ± 4.8 +14.1 ± 5.5
Energy/vitality +9.0 ± 5.0 +13.7 ± 5.9
*Sample size was smaller for the symptoms domain (n ¼ 415)
and the work domain (n ¼ 414).
Figure 2 Subgroup analysis: proportion of patients reporting ‘fair-to-very poor’ response to previous migraine treatment
who reported satisfaction as ‘good-to-excellent’ when switched to eletriptan 40 mg
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butes of acute migraine treatment also rated degree
of pain relief (22%) and rapid onset of relief (15%)
most highly (18). Therefore, both patients and physi-
cians agree that it is most important that an effective
migraine treatment eradicates pain completely,
reduces pain rapidly and has a long-lasting effect.
Our study found treatment with eletriptan 40 mg
was associated with high levels of satisfaction in
approximately two-thirds of patients for degree of
pain relief, time of pain relief, duration of relief, time
to return to usual activities and relief of associated
symptoms. In contrast, only 49% of patients reported
high levels of satisfaction with previous treatment for
degree of pain relief, and only one-third of patients
reported high levels of satisfaction for the other out-
comes.
The high satisfaction reported with eletriptan
40 mg most likely reﬂects the high 2-h and sustained
(48-h) headache response, and pain-free response
rates recorded. We would expect presence/absence of
a 2-h headache/pain-free response to inﬂuence satis-
faction with time of pain relief and time to return to
usual activities, presence/absence of pain-free
response (at 2 and 48 h) to inﬂuence satisfaction
with degree of headache pain relief, and presence/
absence of sustained headache/pain-free response to
inﬂuence satisfaction with duration of relief. Indeed,
the 2-h headache response rate (62%) and the pro-
portion of patients reporting satisfaction as ‘good-to-
excellent’ for time to headache pain relief (63%) are
approximately equal. The high levels of satisfaction
reported by patients treated with eletriptan also
reﬂect improvements in both QOL, as measured by
the MQOLQ, and in functioning, as measured by the
FAIM-A&P scale. In particular, improved QOL and
functioning would impact on satisfaction with time
to return to usual activities, which was rated as
‘good-to-excellent’ in 66% of study participants.
Eletriptan was also effective in achieving high lev-
els of satisfaction in patients reporting low satisfac-
tion with previous migraine therapy and in patients
who experienced poor tolerability. Thus, switching a
patient from a suboptimally effective triptan to ele-
triptan can be a useful treatment strategy, a ﬁnding
consistent with those of previous switch studies
(19,20).
The study was limited by the following important
factors: (i) the study was not double blind, and had no
parallel-group active comparator or placebo control;
rather it was an open-label study speciﬁcally focusing
on satisfaction with eletriptan 40 mg. Open-label
studies may be affected by patients’ views about the
study medication, whether positive or negative. The
fact that eletriptan is a new treatment may also affect
the way it is perceived relative to longer established
therapies, (ii) patient perceptions of eletriptan treat-
ment were based on only one treated attack, which
may or may not have been ‘typical’ for that patient,
(iii) patient ratings of their previous migraine treat-
ment were retrospective, which may have introduced
recall bias, (iv) furthermore, although patients were
asked to rate their ‘usual’ therapy, their response may
have been inﬂuenced by their experience of a number
of treatments, not just their most commonly utilised
therapy. Thus the results of the baseline MSQ may
reﬂect general impressions with previous treatments
used and (v) we did not evaluate whether patients on
different previous treatments reported different satis-
faction results with eletriptan. A patient’s prior experi-
ence with treatment may affect their rating of a new
therapy. For example, patients previously receiving
migraine-speciﬁc drugs such as triptans or ergotamine
may have had higher expectations of eletriptan than
patients previously treated with general analgesics.
Despite these limitations, our study demonstrates
the utility of patient-weighted satisfaction scores in
assessing migraine treatment effectiveness. It also
shows that eletriptan 40 mg produces higher levels of
satisfaction than previous migraine therapy on the
items identiﬁed as important to patients. The prefer-
ence weighting methodology used in the current
study is a promising approach for measuring
patient-rated outcomes, as it customises standard
efﬁcacy assessments based on individualised patient
inputs. Consequently, the real-world effectiveness of
treatment can be assessed on an individual patient
basis in terms of the factors that are most important
to them.
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